Highlights Lotus Pharmaceutical Co., Ltd. Taipei Exchange

Equities

1795

TW0001795003

End-of-day quote Taipei Exchange Other stock markets 23:00:00 12/12/2019 GMT			5-day change	1st Jan Change
108 ^TWD	+0.47%		-4.42%	-.--%

05-11	Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-26	Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-11	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01-14	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15/08/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	31/07/23	CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023	16/06/23	CI
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	05/06/23	CI
Lotus Pharmaceutical Co., Ltd. Approves to Enter, Jointly with Alvogen US, into an Exclusive Agreement with NeuroRx Inc. to Develop, Manufacture and Commercialize NRX-101	03/06/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI
Lotus Pharmaceutical Co., Ltd. Receives Final Approval for its ANDA for Lenalidomide Capsules, 2.5 Mg and 20 Mg from US FDA	07/03/23	CI
Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea	02/02/23	MT
Lotus Pharmaceutical Co., Ltd. Receives Tentative Approval for Its ANDA for Nintedanib Capsules, 100 Mg and 150 Mg, from the US FDA	15/01/23	CI
Lotus Pharmaceutical Co., Ltd. acquired alimta business of Eli Lilly and Company.	30/12/22	CI
Lotus Pharmaceutical Co., Ltd. entered into an agreement to acquire alimta business of Eli Lilly and Company for $62 million.	12/12/22	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Lotus Pharmaceutical Co., Ltd. Receives the Final Approval for Its ANDA for Lenalidomide Capsules, 5 Mg, 10 Mg, 15 Mg and 25 Mg from the US FDA	01/09/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lotus Pharmaceutical Co., Ltd. Taipei Exchange

Equities

1795

TW0001795003

Highlights

Filters